High-stakes Novo Nordisk Alzheimer’s studies could yield answers on GLP-1 benefit – Reuters
High-stakes Novo Nordisk Alzheimer’s studies could yield answers on GLP-1 benefit Reuters
A step forward for knee osteoarthritis pain . . . and other research
Liraglutide for minor acute ischaemic strokePeople with diabetes who have a minor acute ischaemic stroke are at high risk of having another stroke within three months. A small open label trial set in China suggests that this may be reduced by liraglutide, the glucagon-like peptide-1 (GLP-1) receptor agonist. Of the 317 patients in the liraglutide […]
Daily fat busting PILL made by Mounjaro maker dramatically slashes weight AND blood sugar levels, latest trial shows
The once-a-day pill belongs to class of medications called GLP-1 agonists, like Mounjaro, which suppress appetite and make users feel fuller for longer.
Equinox has too many next big bets to count
It took the Equinox Group—the parent company of luxury gym chain Equinox, Equinox hotels, and Soulcycle—around five years to recover from COVID. But the company has recovered, claiming that 2025 will be a record year from a profitability perspective. This year, it announced big plans for expansion. Harvey Spevak, executive chairman and managing partner of […]
Researchers move closer to matching patients with GLP-1 drug that works best for them – Reuters
Researchers move closer to matching patients with GLP-1 drug that works best for them Reuters
High-stakes Novo Nordisk Alzheimer’s studies could yield answers on GLP-1 benefit
Post Content
[Articles] Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
In adults with obesity or overweight and type 2 diabetes, statistically superior reduction in bodyweight compared with placebo was demonstrated by once-daily orforglipron as an adjunct to lifestyle modification, with a safety profile similar to other GLP-1 receptor agonists.
New daily fat jab PILL is ‘cheaper, highly effective and has fewer side effects’
A WEIGHT loss pill set to be available next year will be a cheaper, easier and effective alternative to Mounjaro injections, say experts. They hope orforglipron will “open the door to treatment for all”. The one-a-day tablet banishes hunger cravings and boosts fat burning and works the same way as blockbuster GLP-1 injections including Ozempic…
Daily fat busting PILL made by Mounjaro maker dramatically slashes weight AND blood sugar levels, latest trial shows
The once-a-day pill belongs to class of medications called GLP-1 agonists, like Mounjaro, which suppress appetite and make users feel fuller for longer.
Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly?
Key Points Novo Nordisk and Eli Lilly make the world’s top-selling weight loss drugs. These products have driven the companies’ revenue growth in recent years. 10 stocks we like better than Eli Lilly › Investors generally buy pharmaceutical stocks to add an element of safety to their portfolios. People need their medicines regardless of the […]